GlassScriptPhysician profile
Mary S Doellman
NPI 1417117854
$5,982.51
in general payments reported to CMS, 2019-2025
19 companies · $3,308 in 2025
The $3,308 reported for 2025 was more than what 94% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $16.56 · 2021: $198 · 2022: $324 · 2023: $251 · 2024: $1,593 · 2025: $3,308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,712 · Travel and Lodging: $2,440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,711.59 |
| Travel and Lodging | $2,439.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $1,386.60 | 2024-2025 | |
| Inspire Medical Systems, INC. | $1,129.25 | 2024-2025 | Inspire |
| Smith+Nephew, INC. | $1,041.98 | 2023-2025 | Tula, Halo |
| Integra Lifesciences Corporation | $686.08 | 2024-2025 | Relieva Spinplus Nav, Inspira Air, Acclarent Aera |
| Stryker Corporation | $296.75 | 2019-2025 | Scopis Ent, Xpress Loprofile, Clarifix |
| Genzyme Corporation | $263.75 | 2020-2025 | |
| Glaxosmithkline, LLC. | $257.74 | 2021-2025 | Nucala |
| Astrazeneca Pharmaceuticals LP | $206.77 | 2019-2025 | Fasenra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $204.25 | 2021-2025 | Dupixent |
| Cochlear Americas | $150.29 | 2019 | |
| Acclarent, INC | $108.63 | 2019-2023 | Trudi Nav Cable |
| Optinose US, INC. | $65.65 | 2022-2023 | |
| Amgen INC. | $53.64 | 2022-2025 | Tezspire |
| Alk-Abello, INC | $42.71 | 2023 | Standardized Mite D. Farinae, Timothy, Standardized, Pre-Pen |
| Heron Therapeutics, INC. | $23.92 | 2025 | Zynrelef |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $18.60 | 2024 | |
| Genentech USA, INC. | $16.73 | 2022 | |
| Medtronic, INC. | $16.39 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $12.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Doellman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.